MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
Genentech and NVIDIA enter AI research collaboration
November 22, 2023Research and Development AI, Genentech, Pharmacy, research collaboration
Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA that is intended to pair …
Merck to acquire Caraway Therapeutics for up to $610m
November 22, 2023Business Services Caraway Therapeutics, MSD, Merck, Pharmacy, acquisition
Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced that they have entered into …
GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trialsÂ
November 21, 2023Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …
AstraZeneca launches health-tech business, Evinova
November 21, 2023Business Services AstraZeneca, Pharmacy, health-tech
AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is hoped will become a leading …
Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
November 20, 2023Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …
Astellas Pharma to acquire Propella Therapeutics for $175m
November 20, 2023Business Services Astellas Pharma, Oncology, Properlla Therapeutics, acquisition
Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger agreement in which Astellas will …
FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment
November 17, 2023Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …
FDA approves Merck’s Keytruda for gastric cancer treatment
November 17, 2023Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda
Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …
FDA approves BMS’s Augtyro for lung cancer treatment
November 16, 2023Medical Communications FDA, Oncology, bristol myers squibb, lung cancer
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …
Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site
November 16, 2023Business Services Fresenius Kabi, Pharmacy, Prange Group, acquisition
Prange Group and Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for their acquisition of its …
Kesin Pharma’s Likmez approved by FDA
November 15, 2023Medical Communications Kesin Pharma, Likmez, Pharmacy, Saptalis Pharmaceuticals, antibiotic
Kesin Pharma has announced that the US Food and Drug Administration (FDA) has approved Likmez (metronidazole) oral suspension, 500mg/5mL, for …
Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada
November 15, 2023Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar
Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to …
Autifony announces global license and collaboration agreement with Jazz Pharmaceuticals
November 14, 2023Business Services Autifony, Neurology, collaboration, jazz pharmaceuticals, neurological disorders
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, …
Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment
November 14, 2023Medical Communications Health Canada, Medision Pharma, Rare Diseases, ipsen, pruritis
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the treatment of pruritis in patients …
Enhanc3D Genomics appoints Hazel Jones as chief operating officer
November 14, 2023Business Services Enhanc3D Genomics, Hazel Jones, chief operating officer
Enhanc3D Genomics has announced the appointment of Hazel Jones as chief operating officer. This appointment marks part of the company’s …
Anthony Johnson appointed NanoSyrinx’s non-executive director
November 14, 2023Business Services Anthony Johnson, NanoSyrinx, non-executive director
NanoSyrinx has announced the appointment of Anthony Johnson MD to its board as non-executive director. This appointment marks part of …
GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment
November 13, 2023Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis
GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
November 13, 2023Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …
Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment
November 10, 2023Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
